Trial Profile

The Phase I Efficacy and Safety Clinical Study of CD19/CD22-Dual-STAR-T Cells in Relapsed and Refractory B-ALL

Status: Suspended

Phase of Trial: Phase I

Latest Information Update: 30 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti-CD19 anti-CD 22 STAR T cell therapy-China Immunotech (Primary) ; Cyclophosphamide; Fludarabine
Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions

Most Recent Events

29 Jan 2022 Planned End Date changed from 10 Nov 2022 to 10 Dec 2022.
29 Jan 2022 Planned primary completion date changed from 10 Aug 2022 to 1 Oct 2022.
29 Jan 2022 Planned initiation date changed from 10 Aug 2020 to 1 May 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com